XML 21 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1Close
CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
OPERATING CASH FLOW      
Net earnings (loss) from Cont Ops $ 79 $ 73 $ (401)
Adjustments to reconcile net earnings (loss) from Cont Ops to operating cash flow:      
Impairment 0 (24) 290
(Gain) loss on pension settlement 0 (42) 198
Depreciation and amortization 74 73 74
(Earnings) loss from equity method investments, net of distributions (9) (15) (8)
(Gain) loss on sales of assets (including Stork and AMECO-South America in 2023 and AMECO-North America in 2022) 150 (35) (2)
Stock-based compensation 48 19 32
Deferred taxes (13) 17 28
Changes in assets and liabilities (114) (46) (197)
Other (3) 11 11
Operating cash flow 212 31 25 Close
INVESTING CASH FLOW      
Purchases of marketable securities (426) (428) (149)
Proceeds from sales and maturities of marketable securities 285 364 45
Capital expenditures (106) (75) (75)
Proceeds from sales of assets (net of cash divested) (5) 95 146
Investments in partnerships and joint ventures (33) (53) (80)
Other 8 19 (9)
Investing cash flow (277) (78) (122) Close
FINANCING CASH FLOW      
Proceeds from issuance of 2029 Notes, net of issuance costs 560 0 0
Capped call transactions related to 2029 Notes (73) 0 0
Purchases and retirement of debt (249) (41) (525)
Proceeds from NuScale de-SPAC transaction 0 341 0
Proceeds from sale of NuScale interest 0 107 0
Proceeds from issuance of CPS 0 0 582
Dividends paid on CPS (29) (39) (19)
Make-whole payment on conversion of CPS (27) 0 0
Distributions paid to NCI (53) (60) (109)
Capital contributions by NCI 10 21 202
Other (12) (14) (9)
Financing cash flow 127 315 122 Close
Effect of exchange rate changes on cash 18 (38) (15) Close
Increase in cash and cash equivalents 80 230 10 Close
Cash and cash equivalents at beginning of year 2,439 2,209 2,199
Cash and cash equivalents at end of year $ 2,519 $ 2,439 $ 2,209